TY - JOUR
T1 - Impact of Pretransplantation 18F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma
AU - Center for International Blood and Marrow Transplant Research Lymphoma Working Committee
AU - Bachanova, Veronika
AU - Burns, Linda J.
AU - Ahn, Kwang Woo
AU - Laport, Ginna G.
AU - Akpek, Görgün
AU - Kharfan-Dabaja, Mohamed A.
AU - Nishihori, Taiga
AU - Agura, Edward
AU - Armand, Philippe
AU - Jaglowski, Samantha M.
AU - Cairo, Mitchell S.
AU - Cashen, Amanda F.
AU - Cohen, Jonathon B.
AU - D'Souza, Anita
AU - Freytes, César O.
AU - Gale, Robert Peter
AU - Ganguly, Siddhartha
AU - Ghosh, Nilanjan
AU - Holmberg, Leona A.
AU - Inwards, David J.
AU - Kanate, Abraham S.
AU - Lazarus, Hillard M.
AU - Malone, Adriana K.
AU - Munker, Reinhold
AU - Mussetti, Alberto
AU - Norkin, Maxim
AU - Prestidge, Tim D.
AU - Rowe, Jacob M.
AU - Satwani, Prakash
AU - Siddiqi, Tanya
AU - Stiff, Patrick J.
AU - William, Basem M.
AU - Wirk, Baldeep
AU - Maloney, David G.
AU - Smith, Sonali M.
AU - Sureda, Anna M.
AU - Carreras, Jeanette
AU - Hamadani, Mehdi
N1 - Publisher Copyright:
© 2015 American Society for Blood and Marrow Transplantation.
PY - 2015/9/1
Y1 - 2015/9/1
N2 - Assessment with 18F-fluorodeoxy glucose (FDG)-positron emission tomography (PET) before hematopoietic cell transplantation (HCT) for lymphoma may be prognostic for outcomes. Patients with chemotherapy-sensitive non-Hodgkin lymphoma (NHL) undergoing allogeneic HCT reported to the Center of International Blood and Marrow Transplantation Registry between 2007 and 2012 were included. Pre-HCT PET status (positive versus negative) was determined by the reporting transplantation centers. We analyzed 336 patients; median age was 55 years and 60% were males. Follicular lymphoma (n = 104) was more common than large cell (n = 85), mantle cell (n = 69), and mature natural killer or T cell lymphoma (n = 78); two thirds of the cohort received reduced-intensity conditioning; one half had unrelated donor grafts. Patients underwent PET scanning a median of 1 month (range, .07 to 2.83 months) before HCT; 159 were PET positive and 177 were PET negative. At 3 years, relapse/progression, progression-free survival (PFS), and overall survival (OS) in PET-positive versus PET-negative groups were 40% versus 26%; P = .007; 43% versus 47%; P = .47; and 58% versus 60%; P = .73, respectively. On multivariate analysis, a positive pretransplantation PET was associated with an increased risk of relapse/progression (risk ratio [RR], 1.86; P = .001) but was not associated with increased mortality (RR, 1.29, 95% confidence interval [CI], .96 to 1.7; P = .08), therapy failure (RR, 1.32; 95% CI, .95 to 1.84; P = .10), or nonrelapse mortality (RR, .75; 95% CI, .48 to 1.18; P = .22). PET status conferred no influence on graft-versus-host disease. A positive PET scan before HCT is associated with increased relapse risk but should not be interpreted as a barrier to a successful allograft. PET status does not appear to predict survival after allogeneic HCT for NHL.
AB - Assessment with 18F-fluorodeoxy glucose (FDG)-positron emission tomography (PET) before hematopoietic cell transplantation (HCT) for lymphoma may be prognostic for outcomes. Patients with chemotherapy-sensitive non-Hodgkin lymphoma (NHL) undergoing allogeneic HCT reported to the Center of International Blood and Marrow Transplantation Registry between 2007 and 2012 were included. Pre-HCT PET status (positive versus negative) was determined by the reporting transplantation centers. We analyzed 336 patients; median age was 55 years and 60% were males. Follicular lymphoma (n = 104) was more common than large cell (n = 85), mantle cell (n = 69), and mature natural killer or T cell lymphoma (n = 78); two thirds of the cohort received reduced-intensity conditioning; one half had unrelated donor grafts. Patients underwent PET scanning a median of 1 month (range, .07 to 2.83 months) before HCT; 159 were PET positive and 177 were PET negative. At 3 years, relapse/progression, progression-free survival (PFS), and overall survival (OS) in PET-positive versus PET-negative groups were 40% versus 26%; P = .007; 43% versus 47%; P = .47; and 58% versus 60%; P = .73, respectively. On multivariate analysis, a positive pretransplantation PET was associated with an increased risk of relapse/progression (risk ratio [RR], 1.86; P = .001) but was not associated with increased mortality (RR, 1.29, 95% confidence interval [CI], .96 to 1.7; P = .08), therapy failure (RR, 1.32; 95% CI, .95 to 1.84; P = .10), or nonrelapse mortality (RR, .75; 95% CI, .48 to 1.18; P = .22). PET status conferred no influence on graft-versus-host disease. A positive PET scan before HCT is associated with increased relapse risk but should not be interpreted as a barrier to a successful allograft. PET status does not appear to predict survival after allogeneic HCT for NHL.
KW - Allogeneic transplantation
KW - Non-Hodgkin lymphoma
KW - Positron emission tomography
UR - http://www.scopus.com/inward/record.url?scp=84938993122&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2015.05.007
DO - 10.1016/j.bbmt.2015.05.007
M3 - Article
C2 - 25983043
AN - SCOPUS:84938993122
SN - 1083-8791
VL - 21
SP - 1605
EP - 1611
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 9
ER -